...T cell lymphoma. Theratechnologies regains Egrifta rights Theratechnologies Inc. (TSX:TH) regained distribution rights to Egrifta tesamorelin...

...infarction (MI). Theratechnologies Inc., AOP Orphan Pharmaceuticals AG, BL&H Co. Ltd. and Sanofi market Egrifta tesamorelin...

...Theratechnologies granted BL&H rights to develop and commercialize Egrifta tesamorelin in South Korea to treat HIV-associated...
...through named patient sales programs in the interim. Theratechnologies is responsible for manufacturing and supplying Egrifta...

...Egrifta tesamorelin to treat lipodystrophy in HIV patients is now available in European countries as part...
...and Canada. Earlier this year, Theratechnologies granted AOP Orphan exclusive rights to develop and commercialize Egrifta...

...to develop and commercialize Egrifta tesamorelin in select countries within Europe. AOP Orphan will distribute Egrifta...

...Theratechnologies said it sent a first shipment of 1 mg Egrifta tesamorelin to its U.S. distributor...
...treat excess abdominal fat in HIV patients with lipodystrophy. The company said new batches of Egrifta...
...U.S. rights to the product in May. In February, Theratechnologies said it expected inventory of Egrifta...

...The companies completed the return of U.S. rights to Egrifta tesamorelin to Theratechnologies from Merck's EMD...
...HIV patients with lipodystrophy (see BioCentury, Dec. 23, 2013). Separately, Theratechnologies regained Canadian rights to Egrifta...
...provide financial compensation to any parties involved. On April 30, Theratechnologies said Health Canada approved Egrifta...

...Theratechnologies said on Feb. 14 that it expects inventory of Egrifta tesamorelin to be depleted "in...
...due to manufacturing delays and production issues and that it would temporarily cease manufacture of Egrifta...
...when it would resume manufacturing. In December, Theratechnologies said it would regain U.S. rights to Egrifta...

...C$0.50 after Theratechnologies said on Feb. 14 that it expects inventory of lipodystrophy drug Egrifta tesamorelin...
...weeks" due to manufacturing delays and production issues. The company has temporarily ceased manufacture of Egrifta...

...Theratechnologies will regain U.S. rights to Egrifta tesamorelin from Merck's EMD Serono Inc. subsidiary for $20...
...amount is reached or until Jan. 1, 2024. Theratechnologies said that regaining U.S. rights to Egrifta...
...TSX:TH), Montreal, Quebec Merck KGaA (Xetra:MRK), Darmstadt, Germany Theratechnologies will regain U.S. rights to Egrifta tesamorelin...